Cargando…

IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status

The immunosuppressive tumor microenvironment (TME) does not allow generation and expansion of antitumor effector cells. One of the potent immunosuppressive factors present in the TME is the indoleamine-pyrrole 2,3-dioxygenase (IDO) enzyme, produced mainly by cancer cells and suppressive immune cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nandre, Rahul, Verma, Vivek, Gaur, Pankaj, Patil, Veerupaxagouda, Yang, Xingdong, Ramlaoui, Zainab, Shobaki, Nour, Andersen, Mads Hald, Pedersen, Ayako Wakatsuki, Zocca, Mai-Britt, Mkrtichyan, Mikayel, Gupta, Seema, Khleif, Samir N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381100/ https://www.ncbi.nlm.nih.gov/pubmed/35290437 http://dx.doi.org/10.1158/2326-6066.CIR-21-0457

Ejemplares similares

CD4 responses against IDO
por: Andersen, Mads Hald
Publicado: (2012)

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8(+) and CD4(+) T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
por: Dey, Souvik, et al.
Publicado: (2020)

Immune combinational therapy targeting OX40 and IDO synergistically enhances efficacy of a cancer vaccine
por: Berrong, Zuzana, et al.
Publicado: (2014)

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2021)

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2022)

Impact of IDO1 and IDO2 on the B Cell Immune Response
por: Merlo, Lauren M. F., et al.
Publicado: (2022)

Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
por: Merlo, Lauren M. F., et al.
Publicado: (2020)

Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans
por: Napolioni, Valerio, et al.
Publicado: (2019)

Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells
por: Marttila, Saara, et al.
Publicado: (2011)

Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use
por: Arinola, Ganiyu Olatunbosun, et al.
Publicado: (2023)

Amyloid β neurotoxicity is IDO1–Kyn–AhR dependent and blocked by IDO1 inhibitor
por: Duan, Zhenzhen, et al.
Publicado: (2020)

Indoleamine 2,3‐dioxygenase (IDO)‐1 and IDO‐2 activity and severe course of COVID‐19
por: Guo, Lihui, et al.
Publicado: (2022)

IDO-GCN2 and autophagy in inflammation
por: McGaha, Tracy L.
Publicado: (2015)

IDO2 in Immunomodulation and Autoimmune Disease
por: Prendergast, George C., et al.
Publicado: (2014)

A road less traveled paved by IDO silencing: Harnessing the antitumor activity of neutrophils
por: Manuel, Edwin R., et al.
Publicado: (2013)

IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
por: Lee, Alexander, et al.
Publicado: (2014)

Correction: IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
por: Lee, Alexander, et al.
Publicado: (2015)

Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients
por: Cao, Tingming, et al.
Publicado: (2022)

Immunological Relevance of the Coevolution of IDO1 and AHR
por: Jaronen, Merja, et al.
Publicado: (2014)

Exploitation of the IDO Pathway in the Therapy of Rheumatoid Arthritis
por: Williams, Richard O.
Publicado: (2013)

IDO1 is an Integral Mediator of Inflammatory Neovascularization
por: Mondal, Arpita, et al.
Publicado: (2016)

Trial watch: IDO inhibitors in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

IDO Targeting in Sarcoma: Biological and Clinical Implications
por: Nafia, Imane, et al.
Publicado: (2020)

IDO and Kynurenine Metabolites in Peripheral and CNS Disorders
por: Huang, Yi-Shu, et al.
Publicado: (2020)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

AKT inhibition mitigates terminal differentiation and preserves central memory phenotype of CD8 T cells
por: Abu Eid, Rasha, et al.
Publicado: (2014)

Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2
por: Lee, Young-Kwan, et al.
Publicado: (2014)

Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keynurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia
por: Chilosi, Marco, et al.
Publicado: (2022)

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2023)

New Insights into IDO Biology in Bacterial and Viral Infections
por: Schmidt, Susanne V., et al.
Publicado: (2014)

On the Non-Redundant Roles of TDO2 and IDO1
por: Puccetti, Paolo
Publicado: (2014)

Targeting Tregs in Malignant Brain Cancer: Overcoming IDO
por: Wainwright, Derek A., et al.
Publicado: (2013)

IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity
por: Merlo, Lauren M.F., et al.
Publicado: (2016)

IDO Expression in Cancer: Different Compartment, Different Functionality?
por: Meireson, Annabel, et al.
Publicado: (2020)

The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS
por: Kashi, Alex A., et al.
Publicado: (2019)

Current Challenges for IDO2 as Target in Cancer Immunotherapy
por: Mondanelli, Giada, et al.
Publicado: (2021)

IDO/kynurenine pathway in cancer: possible therapeutic approaches
por: Abd El-Fattah, Eslam E.
Publicado: (2022)

An adverse tumor-protective effect of IDO1 inhibition
por: Kenski, Juliana C.N., et al.
Publicado: (2023)

Recombinant Lactaptin Induces Immunogenic Cell Death and Creates an Antitumor Vaccination Effect in Vivo with Enhancement by an IDO Inhibitor
por: Troitskaya, Olga, et al.
Publicado: (2020)

(Acetylacetonato)dibromido[2,2-diphenylhydrazin-1-ido(1−)][2,2-diphenylhydrazin-1-ido(2−)]molybdenum(VI)
por: Bustos, Carlos, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ru0ckkp1ib8oestddntchko2mr